ArticleResearch in pharmaceutical sciences2025
Preparation and evaluation of valsartan orodispersible tablets using PVP-K30 and HPMC E3 solid dispersions by the solvent evaporation method.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: Valsartan (Val), administered for hypertension, exhibits poor water solubility, resulting in low oral bioavailability. This study aimed to enhance the dissolution of Val by preparing orodispersible tablets (ODT) using solid dispersion (SD) technology with PVP and HPMC as hydrophilic carriers. Experimental approach: After preparation of the SDs and physical mixtures of Val: PVP and Val: HPMC at various ratios, the physicochemical characteristics of these mixtures were analyzed. Then, the ODTs were prepared using the best SD sample and evaluated through USP tests. Findings/Results: The saturation solubility of Val: PVP 1:1 and 1:2 at pH 6.8 was notably higher than that of pure Val. The SDs exhibited a superior dissolution rate compared to pure Val and its physical mixtures. Increasing the drug/carrier ratio resulted in a decrease in the percentage of drug in SD, with Val: PVP 1:1 SD showing significantly higher drug loading percentage compared to other formulations. All formulations exhibited entrapment efficiencies above 80%. Also, the flow of the SDs was good based on the Hausner ratio. Conclusion and implications: The SDs exhibited more favorable attributes compared to pure Val and its physical mixtures. The research suggests that PVP and HPMC are effective carriers for improving the solubility and dissolution rate of Val. Additionally, mannitol was identified as a beneficial excipient for achieving the desired properties of ODTs. The findings can be applied to other drugs with similar solubility issues, paving the way to improve therapeutic outcomes for patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.